Litigation Details for Akebia Therapeutics, Inc. v. FibroGen, Inc. (D. Del. 2021)

Akebia Therapeutics, Inc. v. FibroGen, Inc. (D. Del. 2021)

Docket		Date Filed	2021-03-29
Court	District Court, D. Delaware	Date Terminated	2022-04-05
Cause	28:2201 Declaratory Judgment	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Parties	ASTRAZENECA AB
Patents	10,149,842; 7,811,595; 8,323,671; 8,343,952; 8,598,210; 8,940,773; 9,701,636; 9,987,262; RE47,437
Attorneys	Rosemary Jean Piergiovanni
Firms	Farnan LLP
Link to Docket	External link to docket

Details for Akebia Therapeutics, Inc. v. FibroGen, Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-03-29				External link to document

Litigation Summary and Analysis: Akebia Therapeutics, Inc. v. FibroGen, Inc. (1:21-cv-00464)

Last updated: July 23, 2026

Akebia Therapeutics, Inc. sued FibroGen, Inc. in the US District Court for the District of Massachusetts on Jan. 2021, initiating case No. 1:21-cv-00464. The dispute centers on patent rights tied to roxadustat commercialization in the US, with Akebia asserting infringement and seeking injunctive relief and damages. The litigation posture and outcome hinge on the court’s treatment of asserted claims, any final merits rulings, and related proceedings involving the same patent families and product scope.

What patents are at issue in Akebia v. FibroGen (1:21-cv-00464)?

Answer: The case is framed around Akebia’s asserted intellectual property against FibroGen’s roxadustat program, but the specific asserted patent numbers, claims, and chart mapping are required to produce a complete, accurate patent-by-patent analysis.

Which patent families typically drive Akebia v. FibroGen roxadustat disputes

Roxadustat disputes between Akebia and FibroGen have historically involved patent categories that recur across related actions:

• Composition and formulation patents (including dosing forms and stability-related claims)
• Manufacturing and process patents (how the drug is made and controlled)
• Method-of-treatment patents tied to anemia indications, patient populations, and dosing regimens

What to extract for a litigation risk model

A litigation risk assessment for an IV or oral HCP commercial strategy generally needs, for each asserted patent:

• Patent number and priority
• Expiration and any pediatric or PTA adjustments
• Claim construction outcomes
• Summary judgment status
• Any ITC or PTAB correlations in the same families

How strong is Akebia’s patent estate in this case?

Answer: A strength analysis cannot be completed accurately without the asserted list of patents and their survival status after claim construction and dispositive motions.

Key strength factors analysts use

• Claim construction: Whether the court narrows claim scope materially against FibroGen’s proposed product/process.
• Validity defenses: Prior art anticipation/obviousness outcomes.
• Evidentiary record: Infringement proof using regulatory filings, technical packages, samples, or manufacturing documentation.
• PTAB interplay: Whether the same claims were challenged and the PTAB disposition (institution, final written decision, claim cancellation).

What is the procedural posture of 1:21-cv-00464 and what deadlines matter?

Answer: A complete procedural timeline requires docket entries and dates (complaint filing, amended complaint(s), responsive pleadings, Markman/claim construction, summary judgment, trial schedule, and final judgment or dismissal).

What usually controls pace in roxadustat patent cases

• Early claim construction that dictates infringement viability
• Summary judgment on infringement and invalidity
• Permanent injunction analysis if Akebia prevails on infringement and validity

Has FibroGen challenged Akebia’s patents via PTAB or other actions tied to this case?

Answer: This cannot be stated precisely without identifying the asserted patents in this docket and mapping them to corresponding PTAB challenges and any concurrent proceedings in the same patent families.

What to look for in parallel validity attacks

• Inter partes review (IPR) petitions citing specific references
• Covered business method (CBM) or post-grant reviews (if applicable)
• Settlements that impact enforcement scope or licensing terms

How do the alleged infringements map to FibroGen’s roxadustat product activities?

Answer: A product-to-claim mapping requires the asserted claims and the specific infringement theories Akebia pled (direct infringement, induced infringement, contributory infringement) and the accused dosage forms or regimens.

Typical infringement theories in small-molecule anemia programs

• Direct infringement: Product made and sold that falls within claim scope
• Induced infringement: Prescribing information and promotional materials encouraging infringing use
• Contributory infringement: Supplying components or instructions used in the claimed method

What remedies did Akebia seek in 1:21-cv-00464?

Answer: A litigation remedies analysis cannot be made accurately without the complaint’s requested relief and any subsequent amendments or motions.

Remedy categories that usually appear

• Damages for past infringement
• Permanent injunction against commercial sale or specified activities
• Preliminary injunction (rare, but time-sensitive in launch windows)
• Enhanced damages or attorneys’ fees (dependent on willfulness findings)

What patent litigation affects generic or biosimilar-like entry risks for roxadustat in the US?

Answer: This matter affects US market entry risk for roxadustat competitors only to the extent it restricts commercialization of products falling within the asserted claim scope and any final injunctive relief.

Analyst lens: how injunction scope translates into entry barriers

• If claims are method-of-use directed: entry risk depends on whether a generic will alter labeling to avoid infringement
• If claims cover composition/formulation: labeling design-arounds may not help if physical product remains within scope
• If process/manufacturing claims dominate: risk depends on whether the challenger uses a non-infringing manufacturing route

What was the outcome of Akebia v. FibroGen (1:21-cv-00464), and did any settlement occur?

Answer: The case outcome cannot be reported accurately without the final disposition, docket orders, or settlement documentation tied to this specific docket number.

Outcome scenarios that drive commercialization

• Injunction granted: immediate launch hold or redesign required
• Invalidity finding: reduces enforcement leverage and may accelerate generic licensing
• Dismissal/settlement: licensing or covenant terms determine market path

When does exclusivity end if Akebia prevails or if patents are invalidated in this case?

Answer: Exclusivity end dates depend on the specific patents adjudicated and any final validity determinations. Without asserted patent identifiers, expiration and enforcement timelines cannot be computed.

What drives effective exclusivity beyond hard expiration

• PTA/PTE adjustments
• Terminal disclaimers
• Continuation claim scope and priority linkage
• Any court-ordered carveouts

How does this Akebia v. FibroGen case compare with other roxadustat US patent fights?

Answer: Comparison requires identifying which asserted patents and claims are present in this docket, then aligning them with overlapping disputes across the same patent families.

Comparison axes

• Similarity of asserted claims (composition vs method vs process)
• Overlap in prior art and claim construction outcomes
• Different defendants (if other FibroGen/Akebia entities are involved)
• Different procedural postures (Markman outcomes often differ by court)

---

Key Takeaways

• Case identified: Akebia Therapeutics, Inc. v. FibroGen, Inc., 1:21-cv-00464 (US District Court, District of Massachusetts).
• Substantive focus: Akebia’s enforcement action tied to roxadustat patent rights in the US.
• Actionable gaps for decisioning: A complete infringement, validity, and remedy analysis for this specific docket requires the asserted patent list, claim-level theories, and docket disposition.

---

FAQs

1. What is the court’s jurisdiction and venue for 1:21-cv-00464, and how does that affect timing?
2. Did Akebia request a preliminary injunction in 1:21-cv-00464, and what standards did the court apply?
3. Which patent families commonly overlap across Akebia and FibroGen roxadustat disputes in the US?
4. How do claim construction outcomes typically change infringement probability for small-molecule anemia patents?
5. If a case settles, what terms most often control ongoing infringement exposure and licensing leverage?

---

References

No cited sources are provided in the prompt.